| Name | Title | Contact Details |
|---|---|---|
Russell LaMontagne |
President and Chief Executive Officer | Profile |
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.
Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
One Cell Systems is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.